Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease

H. Zhu, X. Wang, M. Wallack, H. Li, I. Carreras, A. Dedeoglu, J. Y. Hur, H. Zheng, H. Li, R. Fine, M. Mwamburi, Xiaoyan Sun, N. Kowall, R. A. Stern, W. Q. Qiu

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Amylin, a pancreatic peptide, and amyloid-beta peptides (Aβ), a major component of Alzheimer's disease (AD) brain, share similar β-sheet secondary structures, but it is not known whether pancreatic amylin affects amyloid pathogenesis in the AD brain. Using AD mouse models, we investigated the effects of amylin and its clinical analog, pramlintide, on AD pathogenesis. Surprisingly, chronic intraperitoneal (i.p.) injection of AD animals with either amylin or pramlintide reduces the amyloid burden as well as lowers the concentrations of Aβ in the brain. These treatments significantly improve their learning and memory assessed by two behavioral tests, Y maze and Morris water maze. Both amylin and pramlintide treatments increase the concentrations of Aβ1-42 in cerebral spinal fluid (CSF). A single i.p. injection of either peptide also induces a surge of Aβ in the serum, the magnitude of which is proportionate to the amount of Aβ in brain tissue. One intracerebroventricular injection of amylin induces a more significant surge in serum Aβ than one i.p. injection of the peptide. In 330 human plasma samples, a positive association between amylin and Aβ1-42 as well as Aβ1-40 is found only in patients with AD or amnestic mild cognitive impairment. As amylin readily crosses the blood-brain barrier, our study demonstrates that peripheral amylin's action on the central nervous system results in translocation of Aβ from the brain into the CSF and blood that could be an explanation for a positive relationship between amylin and Aβ in blood. As naturally occurring amylin may play a role in regulating Aβ in brain, amylin class peptides may provide a new avenue for both treatment and diagnosis of AD.

Original languageEnglish (US)
Pages (from-to)252-262
Number of pages11
JournalMolecular Psychiatry
Volume20
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Islet Amyloid Polypeptide
Intraperitoneal Injections
Amyloid
Alzheimer Disease
Pathology
Peptides
Brain
Amyloid beta-Peptides
Blood-Brain Barrier
Serum

ASJC Scopus subject areas

  • Molecular Biology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease. / Zhu, H.; Wang, X.; Wallack, M.; Li, H.; Carreras, I.; Dedeoglu, A.; Hur, J. Y.; Zheng, H.; Li, H.; Fine, R.; Mwamburi, M.; Sun, Xiaoyan; Kowall, N.; Stern, R. A.; Qiu, W. Q.

In: Molecular Psychiatry, Vol. 20, No. 2, 01.02.2015, p. 252-262.

Research output: Contribution to journalArticle

Zhu, H, Wang, X, Wallack, M, Li, H, Carreras, I, Dedeoglu, A, Hur, JY, Zheng, H, Li, H, Fine, R, Mwamburi, M, Sun, X, Kowall, N, Stern, RA & Qiu, WQ 2015, 'Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease', Molecular Psychiatry, vol. 20, no. 2, pp. 252-262. https://doi.org/10.1038/mp.2014.17
Zhu, H. ; Wang, X. ; Wallack, M. ; Li, H. ; Carreras, I. ; Dedeoglu, A. ; Hur, J. Y. ; Zheng, H. ; Li, H. ; Fine, R. ; Mwamburi, M. ; Sun, Xiaoyan ; Kowall, N. ; Stern, R. A. ; Qiu, W. Q. / Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease. In: Molecular Psychiatry. 2015 ; Vol. 20, No. 2. pp. 252-262.
@article{92c6b75682eb4c89b9031286c0a26c6f,
title = "Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease",
abstract = "Amylin, a pancreatic peptide, and amyloid-beta peptides (Aβ), a major component of Alzheimer's disease (AD) brain, share similar β-sheet secondary structures, but it is not known whether pancreatic amylin affects amyloid pathogenesis in the AD brain. Using AD mouse models, we investigated the effects of amylin and its clinical analog, pramlintide, on AD pathogenesis. Surprisingly, chronic intraperitoneal (i.p.) injection of AD animals with either amylin or pramlintide reduces the amyloid burden as well as lowers the concentrations of Aβ in the brain. These treatments significantly improve their learning and memory assessed by two behavioral tests, Y maze and Morris water maze. Both amylin and pramlintide treatments increase the concentrations of Aβ1-42 in cerebral spinal fluid (CSF). A single i.p. injection of either peptide also induces a surge of Aβ in the serum, the magnitude of which is proportionate to the amount of Aβ in brain tissue. One intracerebroventricular injection of amylin induces a more significant surge in serum Aβ than one i.p. injection of the peptide. In 330 human plasma samples, a positive association between amylin and Aβ1-42 as well as Aβ1-40 is found only in patients with AD or amnestic mild cognitive impairment. As amylin readily crosses the blood-brain barrier, our study demonstrates that peripheral amylin's action on the central nervous system results in translocation of Aβ from the brain into the CSF and blood that could be an explanation for a positive relationship between amylin and Aβ in blood. As naturally occurring amylin may play a role in regulating Aβ in brain, amylin class peptides may provide a new avenue for both treatment and diagnosis of AD.",
author = "H. Zhu and X. Wang and M. Wallack and H. Li and I. Carreras and A. Dedeoglu and Hur, {J. Y.} and H. Zheng and H. Li and R. Fine and M. Mwamburi and Xiaoyan Sun and N. Kowall and Stern, {R. A.} and Qiu, {W. Q.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1038/mp.2014.17",
language = "English (US)",
volume = "20",
pages = "252--262",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease

AU - Zhu, H.

AU - Wang, X.

AU - Wallack, M.

AU - Li, H.

AU - Carreras, I.

AU - Dedeoglu, A.

AU - Hur, J. Y.

AU - Zheng, H.

AU - Li, H.

AU - Fine, R.

AU - Mwamburi, M.

AU - Sun, Xiaoyan

AU - Kowall, N.

AU - Stern, R. A.

AU - Qiu, W. Q.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Amylin, a pancreatic peptide, and amyloid-beta peptides (Aβ), a major component of Alzheimer's disease (AD) brain, share similar β-sheet secondary structures, but it is not known whether pancreatic amylin affects amyloid pathogenesis in the AD brain. Using AD mouse models, we investigated the effects of amylin and its clinical analog, pramlintide, on AD pathogenesis. Surprisingly, chronic intraperitoneal (i.p.) injection of AD animals with either amylin or pramlintide reduces the amyloid burden as well as lowers the concentrations of Aβ in the brain. These treatments significantly improve their learning and memory assessed by two behavioral tests, Y maze and Morris water maze. Both amylin and pramlintide treatments increase the concentrations of Aβ1-42 in cerebral spinal fluid (CSF). A single i.p. injection of either peptide also induces a surge of Aβ in the serum, the magnitude of which is proportionate to the amount of Aβ in brain tissue. One intracerebroventricular injection of amylin induces a more significant surge in serum Aβ than one i.p. injection of the peptide. In 330 human plasma samples, a positive association between amylin and Aβ1-42 as well as Aβ1-40 is found only in patients with AD or amnestic mild cognitive impairment. As amylin readily crosses the blood-brain barrier, our study demonstrates that peripheral amylin's action on the central nervous system results in translocation of Aβ from the brain into the CSF and blood that could be an explanation for a positive relationship between amylin and Aβ in blood. As naturally occurring amylin may play a role in regulating Aβ in brain, amylin class peptides may provide a new avenue for both treatment and diagnosis of AD.

AB - Amylin, a pancreatic peptide, and amyloid-beta peptides (Aβ), a major component of Alzheimer's disease (AD) brain, share similar β-sheet secondary structures, but it is not known whether pancreatic amylin affects amyloid pathogenesis in the AD brain. Using AD mouse models, we investigated the effects of amylin and its clinical analog, pramlintide, on AD pathogenesis. Surprisingly, chronic intraperitoneal (i.p.) injection of AD animals with either amylin or pramlintide reduces the amyloid burden as well as lowers the concentrations of Aβ in the brain. These treatments significantly improve their learning and memory assessed by two behavioral tests, Y maze and Morris water maze. Both amylin and pramlintide treatments increase the concentrations of Aβ1-42 in cerebral spinal fluid (CSF). A single i.p. injection of either peptide also induces a surge of Aβ in the serum, the magnitude of which is proportionate to the amount of Aβ in brain tissue. One intracerebroventricular injection of amylin induces a more significant surge in serum Aβ than one i.p. injection of the peptide. In 330 human plasma samples, a positive association between amylin and Aβ1-42 as well as Aβ1-40 is found only in patients with AD or amnestic mild cognitive impairment. As amylin readily crosses the blood-brain barrier, our study demonstrates that peripheral amylin's action on the central nervous system results in translocation of Aβ from the brain into the CSF and blood that could be an explanation for a positive relationship between amylin and Aβ in blood. As naturally occurring amylin may play a role in regulating Aβ in brain, amylin class peptides may provide a new avenue for both treatment and diagnosis of AD.

UR - http://www.scopus.com/inward/record.url?scp=85017322903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017322903&partnerID=8YFLogxK

U2 - 10.1038/mp.2014.17

DO - 10.1038/mp.2014.17

M3 - Article

C2 - 24614496

AN - SCOPUS:84930620696

VL - 20

SP - 252

EP - 262

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 2

ER -